Business, Policy & Funding
Breaking news on precision medicine business, policy & funding.
Aptose Biosciences Enters $25M Common Shares Purchase Agreement
The firm will offer up to 12,030,218 common shares for Keystone Capital Partners to sell and is expecting to net around $2.1 million in gross proceeds.
Restore Vision Doses First Retinitis Pigmentosa Patient in Phase I/II Gene Therapy Trial
The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.
In Brief This Week: AstraZeneca, Arrowhead, Immix, Ensoma, Elixirgen, Ideaya Biosciences
News items for the week of Feb. 10, 2025.
Tempus, IFLI Partner to Accelerate Development of Follicular Lymphoma Therapies
The collaboration will involve making a real-world multimodal dataset available in Tempus' Lens platform that researchers can use to accelerate treatment development.
Encoded Therapeutics Lays off 29 Percent of Workforce
The move will provide funds to advance ETX101, a gene therapy the company is developing for SCN1A-positive Dravet syndrome, among other programs.